Roivant Sciences Reports 78% Revenue Decline and $265.9M Net Loss for Q3 2025

Roivant Sciences Ltd. reported a significant decline in financial performance for the three and nine months ended December 31, 2025, as detailed in its latest 10-Q filing. The company generated revenue of $1.999 million for the third quarter, a decrease of approximately 78% from $9.018 million in the same period last year. For the nine-month period, revenue fell to $5.740 million from $21.483 million, marking a decline of about 73%. The company attributed this drop primarily to reduced earnings from license agreements, particularly at its subsidiary Genevant.

Operating expenses also increased, with total expenses rising to $341.152 million for the third quarter, compared to $283.399 million in the prior year, reflecting a 20% increase. For the nine months, operating expenses reached $936.048 million, up from $850.199 million. The increase was driven by higher research and development costs, which rose to $165.380 million for the quarter and $482.867 million for the nine months, largely due to ongoing clinical trials and program-specific costs. General and administrative expenses also saw an uptick, primarily due to share-based compensation and an impairment charge related to the relocation of the company's U.S. headquarters.

Roivant's net loss attributable to the company was $265.891 million for the third quarter, a stark contrast to a net income of $169.381 million in the same quarter of the previous year, largely due to the absence of income from discontinued operations, which had contributed significantly to last year's figures. For the nine-month period, the net loss was $602.765 million, compared to a net income of $34.494 million in the prior year. The company’s accumulated deficit as of December 31, 2025, stood at $694.998 million.

In terms of strategic developments, Roivant completed the sale of its majority-owned subsidiary Telavant in December 2023, which provided approximately $5.2 billion in cash. This transaction has bolstered the company's liquidity, with cash, cash equivalents, and marketable securities totaling approximately $4.5 billion as of December 31, 2025. The company has indicated that this liquidity will support its ongoing operations and development activities, although it may require additional capital in the future to fund its growth initiatives.

Looking ahead, Roivant plans to continue advancing its pipeline of product candidates, which includes several in various stages of clinical trials. The company expects to incur additional losses as it invests in research and development, and it remains focused on potential in-licensing opportunities to enhance its portfolio. The management has expressed confidence in its ability to navigate the challenges ahead, although it acknowledges the inherent uncertainties in the biopharmaceutical industry.